This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Retrospective Analysis Of Linagliptin Data In Sub-populations With Type 2 Diabetes Presented At AACE 22nd Annual Scientific & Clinical Congress

RIDGEFIELD, Conn. and INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two new pooled analyses of phase III data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, presented at the American Association of Clinical Endocrinologists (AACE) 22 nd Annual Scientific & Clinical Congress.

In one retrospective pooled analysis, data were included from Hispanic/Latino adults with type 2 diabetes (T2D), a population that is disproportionately affected by T2D. 1 Data pooled from six phase III studies showed that treatment with linagliptin reduced glucose levels (HbA 1c) versus placebo in this patient population.

In a second retrospective analysis, data were pooled from two phase III studies that included people with long-standing T2D (>/=10 years).  The analysis showed reductions in HbA 1c from baseline with linagliptin versus placebo. 

"Response to treatment can vary between sub-populations of adults with type 2 diabetes," said Christophe Arbet-Engels, MD, PhD, vice president, clinical development and medical affairs metabolic, Boehringer Ingelheim Pharmaceuticals, Inc. "Those with long-standing type 2 diabetes or of Hispanic/Latino origin are often difficult to treat or under-treated."

About Poster No. 1118 - Sub-population of Hispanic/Latino Adults with T2DThe findings from the first presentation were derived from six randomized, double-blind, placebo-controlled phase III studies of linagliptin 5 mg/d given as monotherapy or in addition to common glucose-lowering therapies. 1 Of the six studies included in the analysis, two were 18 weeks in duration and four were 24 weeks in duration. 1 A total of 731 American Hispanic/Latino patients (467 who received linagliptin and 264 who received placebo) were included in the full analysis set (FAS), which was comprised of all randomized patients treated with at least one dose of the study drug, and who had their HbA 1c measured at baseline and at least once during the treatment period. 1 The primary efficacy endpoint was change in HbA 1c from baseline to 18 or 24 weeks. 1  Baseline HbA 1c levels were 8.25% in the linagliptin group and 8.23% in the placebo group. 1

Key findings of the retrospective analysis for the linagliptin treatment group included 1:

  • 0.58% reduction in HbA 1c compared to placebo after 24 weeks of treatment (95% confidence interval [CI]-0.74, -0.42; p<0.0001)
  • 14.6% reported drug-related AEs vs. 18.4% for placebo

About Poster No. 1119 - Sub-population of Adults with Long-standing T2DFor the second retrospective analysis, researchers pooled data from two phase III studies of 202 patients with a reported T2D duration of ≥10 years, who received either linagliptin 5 mg/d (n=122) or placebo (n=80). 2  The average exposure to both treatments was 169 days. 2  A total of 192 patients (117 linagliptin and 75 placebo) were included in the FAS. 2  The primary endpoint was change in HbA 1c from baseline to 24 weeks. 2  Baseline HbA 1c levels were 8.07% in the linagliptin group and 8.45% in the placebo group. 2

Key findings of the retrospective analysis for the linagliptin treatment group included 2:

  • 0.66% reduction in HbA 1c compared to placebo after 24 weeks of treatment (CI: -0.95, -0.38; p<0.0001)
  • 21.3% reported treatment-related AEs vs. 16.3% in the placebo arm

Linagliptin, which is marketed as Tradjenta® (linagliptin) tablets in the U.S., is a once-daily 5mg tablet used along with diet and exercise to improve glycemic control in adults with type 2 diabetes.  Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).  Linagliptin is a DPP-4 inhibitor that does not require dose adjustments, regardless of declining renal function or hepatic impairment.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs